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Pat Doyle1*, Anna Brown2, Valerie Beral2, Gillian Reeves2 and Jane Green2Abstract
Background: Motor neuron disease (MND) is a severe neurodegenerative disease with largely unknown etiology.
Most epidemiological studies are hampered by small sample sizes and/or the retrospective collection of information
on behavioural and lifestyle factors.
Methods: 1.3 million women from the UK Million Women Study, aged 56 years on average at recruitment, were
followed up for incident and/or fatal MND using NHS hospital admission and mortality data. Adjusted relative risks
were calculated using Cox regression models.
Findings: During follow-up for an average of 9.2 years, 752 women had a new diagnosis of MND. Age-specific rates
increased with age, from 1.9 (95% CI 13 – 27) to 12.5 (95% CI 102 – 153) per 100,000 women aged 50–54 to
70–74, respectively, giving a cumulative risk of diagnosis with the disease of 174 per 1000 women between the
ages of 50 and 75 years. There was no significant variation in risk of MND with region of residence, socio-economic
status, education, height, alcohol use, parity, use of oral contraceptives or hormone replacement therapy.
Ever-smokers had about a 20% greater risk than never smokers (RR 119 95% CI 102 to 138, p = 003). There was a
statistically significant reduction in risk of MND with increasing body mass index (pfor trend = 0009): obese women
(body mass index, 30 kg/m2 or more) had a 20% lower risk than women of normal body mass index (20 to <25 Kg/
m2)(RR 078 95% CI 065-094; p = 003). This effect persisted after exclusion of the first three years of follow-up.
Interpretation: MND incidence in UK women rises rapidly with age, and an estimated 1 in 575 women are likely to
be affected between the ages of 50 and 75 years. Smoking slightly increases the risk of MND, and adiposity in
middle age is associated with a lower risk of the disease.
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Motor neurone disease (MND) is a severe neurode-
generative disorder of the human motor system, char-
acterised by the gradual death of upper and lower
motor neurones and a resulting loss of motor func-
tion[1]. Incidence is extremely low below the age of
50, and rises thereafter, with lower rates in women
than in men[2-4].
Little is known about the aetiology of MND. Around
five to ten percent of cases are thought to be familial,
and to date around 13 susceptibility genes and loci have
been identified [5]. Few environmental risk factors have* Correspondence: pat.doyle@lshtm.ac.uk
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reproduction in any medium, provided the orbeen identified, possibly reflecting the difficulties
encountered in epidemiological studies of including
sufficiently large numbers of cases and, in retrospective
studies, knowing whether reported behaviours and expo-
sures had changed as a result of early symptoms of the
disease. The only factor for which there is some evidence
of an association with MND risk is smoking[6-9]. This
study makes use of a large cohort of 1.3 million UK
women aged 56 years, on average, at the time of
recruitment, with prospectively collected exposure
information and with complete follow-up for almost
10 years to obtain incident cases of MND.
Methods
Study population
The Million Women Study (MWS) is a prospective
cohort study of 1.3 million women who were recruitedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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centres in England and Scotland from 1996 to 2001[10].
At recruitment, women completed a questionnaire
(available at www.millionwomenstudy.org) asking about
height, weight, alcohol consumption, and smoking, as
well as socio-demographic details, reproductive history,
and medical history. Height and weight were also directly
measured in a randomly selected subsample of 2772
study participants [11]. Permission to conduct the study
was granted by the Anglia and Oxford Multi-Centre Re-
search Ethics Committee.
Study participants are followed up for cause-specific
hospital admissions and deaths through linkage to
centrally held computerised health records using their
NHS number (a unique identifier) and other identifiers
including date of birth and sex [10]. These linked records
include the NHS central registries for deaths, cancers,
and emigrations; the hospital episodes statistics (HES) in
England [12] ; and the Scottish morbidity records (SMR)
in Scotland [13]. The NHS central registries hold records
of all registered deaths, including the cause of death and
the date of death. The hospital admission databases
contain a record of all NHS inpatient admissions from
April 1997 in England and January 1981 in Scotland.
The cause of death and diagnoses on admission to
hospital were coded by using ICD-10 (the international
classification of diseases, version 10). All study partici-
pants gave signed consent to be included.
MND ascertainment and validation
According to the International Classification of Diseases
(ICD-10) the code G12.2 is the generic code for MND,
and includes diagnoses of amyotrophic lateral sclerosis,
MND, progressive bulbar palsy, primary lateral sclerosis,
and progressive muscular atrophy [14]. We classified
women as having motor neuron disease (MND) if,
during follow-up, they had (i) a hospital admission
record with an ICD10 code of G12.2 and/or (ii) a death
registration with any mention of ICD10 code G12.2.
During our investigations for this report we discovered
an error in the WHO ICD-10 alphabetic coding index
(Volume 3, page 429), where the code for Progressive
Supranuclear Palsy was mistakenly given as code G12.2.
Progressive Supranuclear Palsy is a degenerative disease
of the basal ganglia and not a form of motor neurone
disease (the correct ICD-10 code is G23.1, as given in
Volume 1). We therefore reviewed the written text on all
death certificates with a code G12.2. If the text on the
death certicate mentioned Progressive Supranuclear
Palsy, this was taken to indicate that the woman did not
have MND, and that individual was excluded from the
analysis. Overall, 8% of women who died with a code
G12.2 on their death certificate were excluded as a result
of this process.For women with a G12.2 hospital admission record
and who did not die in the follow-up period, we were
unable to examine text (to exclude any remaining
Progressive Supranuclear Palsy events) because written
records were not available to us. A validation study was
carried out to investigate such cases. Letters were sent to
the General practitioners of a random sample of 89
MND cases ascertained from the HES dataset. General
practitioners were asked to confirm the MND diagno-
sis, or provide information on alternative diagnoses,
from medical notes. Sixty eight (76%) replied and 65
provided information about diseases in these women,
among whom 91% (59) confirmed a diagnosis of
MND. The remaining 9% (6) included 3% (2) with a
diagnosis of Progressive Supranuclear Palsy, 5% (3)
with another neurodegenerative disease, and one with
colon cancer.
Other data definitions
Address at recruitment was used to assign each woman
to one of 4 regions in England and Scotland, roughly
south to north: South West/Thames/Oxford/East Anglia;
West Midlands/Trent; North West/North Yorkshire;
Scotland. Socio-economic status was assessed using
Townsend’s deprivation index, based on postcode of resi-
dence at the time of recruitment, and was categorized
into quintiles[15]. Education was coded according the
highest level of qualification achieved: college/university
or equivalent; nursing/teaching or equivalent; A level; O
level; none of these. BMI was calculated using height and
weight reported at recruitment and participants were
categorized as: underweight (<20 kg/m2); normal (20-
< 25 kg/m2); overweight (25-< 30 kg/m2); obese class I
(30-< 35 kg/m2); and obese class II & III (35+ kg/m2).
Alcohol use reported at recruitment was recorded as
units consumed on average per week: none; <7;7–14;
15 or more units per week. Smoking was also
recorded at the time of recruitment and women were
categorized as never smoker or ever smoker, the latter
category being further split into current and past
smoker. Parity was coded as nulliparous or parous,
use of oral contraceptives as ever or never, and hor-
mone replacement therapy (HRT) as never, past and
current at time of recruitment.
Analysis
Participants were excluded from analyses if they had a
hospital admission record of MND before recruitment,
or had a diagnosis of cancer (except non-melanoma skin
cancer, ICD-10 C44) registered before recruitment.
Woman-years were calculated from the date of recruit-
ment to the date of hospital admission with MND, the
date of death, emigration or the last date of follow-up,
whichever came first. For analyses of MND incidence the
Table 1 Source of information for incident MND cases in
the study population
Incident MND cases
Hospital admission data and death certificate 490 (65%)
Hospital admissions data only* 205 (27%)
Death Certificate only (any mention)** 57 (8%)
- underlying cause of death 54[95%]
- contributing cause of death 3 [5%]
Total cases 752 (100%)
*To 31st March 2008 for England, 31st December 2008 for Scotland.
** To end December 2008.
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and 31st December 2008 for Scotland. For a small
proportion (5%) of women recruited in England before 1
April 1997, we calculated person years from this date as
hospital records were not available in England before
this time.
Age-specific incidence rates were calculated as the
number of new MND cases identified in the cohort
divided by the person years of follow-up within 5 year
age groups. Age-specific rates were compared to those
reported in two recent publications from UK and Europe
[3,4]. Crude cumulative risk for MND was estimated by
summation of age-specific rates over the age range 50 to
74. This estimates the probability of MND up to age 75
in a hypothetical cohort who did not have MND at
age 50.
Cox regression models were applied using the STATA
computing package [16], taking attained age as the
underlying time variable to obtain relative risk (RR) and
corresponding 95% confidence intervals for socio-
demographic, reproductive and behavioral factors, and
BMI. Analyses were adjusted for year of birth (three
groups), region, deprivation, smoking, alcohol use, HRT
use, and BMI. When more than two categories were used
in risk comparisons, results are presented as relative risk
with corresponding floated confidence interval [17].
Analyses of trends in risk of MND by BMI at recruit-
ment were carried out using mean self-reported BMI
within the 5 BMI categories. This analysis was repeated
using measured mean BMI (from the subsample [11])
within the five BMI categories.
To investigate the possibility of women having pro-
dromal MND at the start of follow-up, all analyses were
repeated using a lagging period of 36 months: follow up
for each woman in the cohort was started 36 months
after the date of recruitment.
Results
A total of 1,319,360 women were followed up for an
average of 924 years per woman. During 12 million
woman-years of follow up, 752 women had a new diag-
nosis of MND: 695 had one or more hospital admission
with MND, and 547 had MND recorded on their death
certificate. The majority of women (65%) had MND
recorded both at hospital admission and on their death
certificate, and for only 8% (56) of women was death
certification the only source of information about MND
(Table 1). Ninety-one percent of a random sample of
cases identified via hospital admission records had their
diagnosis confirmed by their general practitioners.
Age-specific rates increased markedly with age, from
190 per 100,000 for women aged 50–54 to 125 per
100,000 for women aged 70–74 (Figure 1). The rate for
women aged 75–79 was 174 per 100,000, based on only17 cases. The estimated cumulative risk of MND be-
tween 50 and 74 years of age was 174 per 1000, equiva-
lent to one in 575 women developing the condition over
this 25 year period.
There was no significant trend in risk of MND with
socio-economic status, education, parity, height, or
alcohol use (Figure 2). Neither was there a significant
association with use of oral contraceptives or hormone
replacement therapy. Rates in Scotland were higher
than the South of England but the confidence interval
spanned one. There was no evidence of variation in risk
by birth cohort. Having ever smoked was associated with
a 20% increased risk (RR 119 95% CI 102-138,
p = 0026) compared to never smokers, and there was no
difference in the increased risk between past and current
smokers (Figure 2). Among current smokers the relative
risks did not differ between those who smoked less than
15 cigarettes per day and those who smoked 15 or more
cigarettes per day (RRs 120, 95% CI 094-155, versus
111, 95% CI 05-147).
There was a clear trend of a reduction in risk of MND
with increasing BMI (Table 2, pfor trend = 0009). Women
classified as underweight at recruitment had 14%
increased MND risk compared with those of normal
BMI at recruitment, with a trend of decreasing risk as
the obesity level increased. Women in the highest BMI
category (BMI class II and III) at recruitment had a 30%
reduction in risk compared with women with normal
BMI at recruitment. Using means of self-reported BMI
at recruitment, there was an estimated 2.3% reduction in
risk of MND for each unit increase in BMI (RR per kg/
m2 = 098, 95% CI 096 to 099, p for trend 001). Results
were very similar when measured mean BMI from the
validation sub-sample was used to estimate the mean
BMI within each BMI category (RR per kg/m2 = 098,
95% CI 096 to 099, p for trend =0011). The lagged ana-
lysis, excluding the first 3 years of follow-up, showed a
similar trend of decreasing MND risk with increasing
BMI, (RR per kg/m2 = 097, 95% CI 095 to 099, p for
trend = 0006). Around one third of woman-years in all
the BMI groups were accrued in the first 3 years
Table 2 Relative risk of MND according to categories of BMI: Main analysis including all data and lagged analysis,
excluding the first three years of follow-up
Main analysis Excluding the first 3 years of follow-up
BMI at recruitment Kg/m2
Number Woman-year Adjusted Relative risk * Number Woman-year Adjusted Relative risk *
cases 1000 s (95% CI) cases 1000 s (95% CI)
Underweight <20.0 32 431 1.14 (0.79-1.65) 26 286 1.14 (0.76-1.71)
Normal 20.0 to <25.0 318 4930 1.00 (0.89-1.12) 262 3296 1.00 (0.88-1.13)
Overweight 25.0 –< 30.0 245 4134 0.87 (0.74-1.03) 183 2757 0.80 (0.66-0.96)
Obese class I 30.0 -< 35.0 81 1462 0.82 (0.64-1.04) 68 972 0.84 (0.64-1.10)
Obese Class II & III 35.0 + 28 594 0.73 (0.49-1.07) 19 393 0.61 (0.38-0.97)
*Adjusted for region, deprivation, year of birth, use of hormone replacement therapy, smoking and alcohol use. ** 0.01< p< 0.05.
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cident in the first three years following recruitment were:
18% for cases underweight at recruitment; 17% for cases
with normal BMI at recruitment; 25% for cases over-
weight at recruitment; 16% for cases who were obese
class I at recruitment; and 32% for cases who were
obese class II&III at recruitment.
Discussion
The size and prospective nature of the Million Women
Study are significant strengths of this study. MND has a
relatively insidious onset so some behavior change mayFigure 1 Age-specific incidence rates of MND in the Million Women S
cases: 31 151 221 238 94. WYS*(1000’s): 1,6357 3,7243 3,6352 2,3430 7501.
125(102-153). * Women-years.result from symptoms, making ascertainment of cases
after the prospective collection of risk factor informa-
tion critical. Case ascertainment using both hospital
admission and death certification sources, combined
with a very high level of diagnostic validation from
general practioner records, adds to the study quality.
And analyses excluding cases diagnosed in the first
3 years after recruitment provide further confidence in
the robustness of the findings.
Prospective follow-up identified 752 MND cases inci-
dent during 9 years of follow-up (mostly in 1997–2008),
making this the largest and most up-to-date study oftudy Cohort. Age of woman: 50–54 55–59 60–64 65–69 70–74. MND
Rate per 105(95% CI) 19(13-27) 41(35-48) 61(53-69) 102(89-15)
Figure 2 Adjusted* rate ratios of MND according to socio-demographic, reproductive and behavioural characteristics of women at the
time of recruitment.
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Incidence rates rose steadily with age giving a cumulative
risk of 1 in 575 women developing the disease in the
25 years from age 50 to 75 years. Rates between 50 and
64 years were similar to recent population-based esti-
mates reported from UK and Europe [3,4], and rates after
age 65 were somewhat higher. There is some evidence of
a continuing increase in MND mortality rates over time
since 1950[18-20], but no differences by birth cohort were
observed here or in another UK study which spanned
15 years [4].
A recent review paper concluded that it was valid for
epidemiological studies to use MND mortality data to
estimate MND incidence within regions [21]. In the
course of our investigations we discovered that 8% of the
ICD-10 code G12.2 on death certificates erroneously
included Progressive Supranuclear Palsy. However the
proportion of death certificates coded to G12.2 with text
indicating Progressive Supranuclear Palsy is not suffi-
ciently large to invalidate analyses of trends in MND
based on death certificates.
We did not find any association between MND and
socio-economic status, education level, parity, height, or
use of alcohol, oral contraceptives or HRT. This is the
first time many of these factors have been investigated in
MND research. The null findings are unlikely to be the
result of low statistical power since this study was large
and well powered to identify moderate associations
should they be present.
We found a highly significant trend of decreasing risk
with increasing BMI at recruitment, an observation
which has not been reported before. Reverse causality,
whereby those with undiagnosed disease at recruitment
loose weight because of the condition, is a possible
explanation for this observation. However some evidence
here argues against this. The association remained the
same in the lagged analysis which excluded all incident
cases in the first three years after recruitment. The
median time between onset of first symptoms and MND
diagnosis is estimated to be around 12 months [22], so
lagging analyses by 3 years should have allowed for the
presence of undiagnosed disease at recruitment, at least
to some extent. The cases diagnosed in the first three
years following recruitment were not clustered dispropor-
tionately in the lower BMI groups, as would be expected
if there was prodromal disease present at recruitment.
Other possible methodological explanations include
confounding and bias resulting from misclassification of
BMI. Uncontrolled confounding is unlikely since so few
risk factors for MND have been identified. With regards
misclassification, BMI in the cohort was based on self
reported height and weight, but comparisons with mea-
sured height and weight in this cohort, have shown that
the effect of measurement error is small [23]. Also, wefound similar trends from BMI trend analyses using
average measured and reported category-specific BMI.
Ever smoking was associated with a modest 20%
increased risk of MND compared to never-smokers.
Among current smokers, relative risks did not differ by
the amount smoked. A review of publications between
1990 and 2009 identified four good quality papers which
were concordant for an effect of smoking on risk of ALS
[6,7]. The author concluded that the level of evidence
was sufficient for smoking to be considered an estab-
lished risk factor for sporadic ALS [7]. A meta-analysis
found a non-significant overall relative risk of 128 (95%
CI 097-168) for smoking and MND risk [8], but after
testing for a range of possible interactions, significant
heterogeneity was found between studies, depending on
the proportion of females in the study. The authors went
on to conduct meta-regression taking the proportion of
females into account, and the resulting model predicted
a smoking-related risk of MND in females (RR 166, 97%
CI 131-210) but not in males (RR 086, 95% CI 071-
103). Their overall relative risk estimate in smokers, of
128, is similar to that found for women in our study,
but their estimate of 1.66 for females is significantly
greater than that found here; this could be because
analyses looking for interactions in multiple subgroups
can sometimes yield extreme results by chance [24].
Conclusion
Overall, in this large prospective study we find a modest
increased risk of MND in ever smokers and a significant
decreasing risk for women with increasing adiposity.
Competing interest
We declare that we have no conflicts of interest.
Authors' contributions
All authors contributed to the design and execution of this work. PD, AB and
VB prepared the report. All authors had an opportunity to contribute to the
interpretation of the results and to the redrafting of the report, and all
authors approved the final report.
Acknowledgments
We thank all the women who participated in the study, the general
practitioners who took blood samples, staff from the NHS Breast Screening
Centres and the Cancer Epidemiology Unit, and Adrian Goodill for the
preparation of the figures. The Million Women Study is supported by Cancer
Research UK and the UK Medical Research Council.
We wish to acknowledge the work of the Million Women Study
Collaborators outlined below.
Million Women Study Steering Committee: Emily Banks, Valerie Beral, Ruth
English, Jane Green, Julietta Patnick, Richard Peto, Gillian Reeves, Martin
Vessey, Matthew Wallis. NHS Breast Screening Centres collaborating in the
Million Women Study (in alphabetical order): Avon, Aylesbury, Barnsley,
Basingstoke, Bedfordshire & Hertfordshire, Cambridge & Huntingdon,
Chelmsford & Colchester, Chester, Cornwall, Crewe, Cumbria, Doncaster,
Dorset, East Berkshire, East Cheshire, East Devon, East of Scotland, East
Suffolk, East Sussex, Gateshead, Gloucestershire, Great Yarmouth, Hereford &
Worcester, Kent (Canterbury, Rochester, Maidstone), Kings Lynn,
Leicestershire, Liverpool, Manchester, Milton Keynes, Newcastle, North
Birmingham, North East Scotland, North Lancashire, North Middlesex, North
Nottingham, North of Scotland, North Tees, North Yorkshire, Nottingham,
Doyle et al. BMC Neurology 2012, 12:25 Page 7 of 7
http://www.biomedcentral.com/1471-2377/12/25Oxford, Portsmouth, Rotherham, Sheffield, Shropshire, Somerset, South
Birmingham, South East Scotland, South East Staffordshire, South Derbyshire,
South Essex, South Lancashire, South West Scotland, Surrey, Warrington
Halton St Helens & Knowsley, Warwickshire Solihull & Coventry, West
Berkshire, West Devon, West London, West Suffolk, West Sussex, Wiltshire,
Winchester, Wirral, and Wycombe. Million Women Study Co-ordinating Centre
staff : Simon Abbott, Naomi Allen, Miranda Armstrong, Krys Baker, Angela
Balkwill, Vicky Benson, Valerie Beral, Judith Black, Anna Brown, Diana Bull,
Benjamin Cairns, Andrew Chadwick, James Chivenga, Barbara Crossley,
Francesca Crowe, Dave Ewart, Sarah Ewart, Lee Fletcher, Laura Gerrard, Adrian
Goodill, Bryony Horner, Isobel Lingard, Jane Green, Winifred Gray, Joy Hooley,
Sau Wan Kan, Carol Keene, Nicky Langston, Maria Jose Luque, Kath Moser,
Lynn Pank, Kirstin Pirie, Gillian Reeves, Emma Sherman, Evelyn Sherry-Starmer,
Moya Simmonds, Helena Strange, Sian Sweetland, Alison Timadjer, Sarah
Tipper, Lyndsey Trickett, Ruth Travis, Joanna Watson, Steve Williams, Lucy
Wright.
Author details
1Faculty of Epidemiology and Population Health, London School of Hygiene
and Tropical Medicine, London, WC1E 7HT, UK. 2Cancer Epidemiology Unit,
University of Oxford, Richard Doll Building, Roosevelt Drive, Oxford, OX3 7LF,
UK.
Received: 15 December 2011 Accepted: 17 April 2012
Published: 6 May 2012References
1. Mitchell JD, Borasio GD: Amyotrophic lateral sclerosis. Lancet 2007,
369:2031–2041.
2. Logroscino G, Traynor BJ, Hardiman O, Chio’ A, Couratier P, Mitchell JD,
Swingler RJ, Beghi E: EURALS. Descriptive epidemiology of amyotrophic
lateral sclerosis: new evidence and unsolved issues. J Neurol Neurosurg
Psychiatry 2008, 79(1):6–11.
3. Logroscino G, Traynor BJ, Hardiman O, Chiò A, Mitchell D, Swingler RJ, Millul
A, Benn E, Beghi E: EURALS. Incidence of amyotrophic lateral sclerosis in
Europe. J Neurol Neurosurg Psychiatry 2010, 81(4):385–390. Epub 2009 Aug 25.
4. Alonso A, Logroscino G, Jick SS, Hernán MA: Incidence and lifetime risk of
motor neuron disease in the United Kingdom: a population-based study.
Eur J Neurol 2009, 16(6):745–751.
5. Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, Burrell JR,
Zoing MC: Amyotrophic lateral sclerosis. Lancet 2011, 377(9769):942–955.
Epub 2011 Feb 4.
6. Armon C: An evidence-based medicine approach to the evaluation of the
role of exogenous risk factors in sporadic amyotropic lateral sclerosis.
Neuroepidemiology 2003, 22:217–228.
7. Armon C: Smoking may be considered an established risk factor for
sporadic ALS. Neurology 2009, 73(20):1693–1698.
8. Alonso A, Logroscino G, Hernán MA: Smoking and the risk of amyotrophic
lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg
Psychiatry 2010, 81(11):1249–1252.
9. Alonso A, Logroscino G, Jick SS, Hernán MA: Association of smoking with
amyotrophic lateral sclerosis risk and survival in men and women: a
prospective study. BMC Neurol 2010, 10:6.
10. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D, Million Women Study
Collaboration: Cancer incidence and mortality in relation to body mass
index in the Million Women Study: cohort study. BMJ 2007, 335
(7630):1134.
11. Armstrong MEG, Spencer EA, Cairns BJ, Banks E, Pirie K, Green J, Wright FL,
Reeves GK, Beral V, for the Million women Study Collaborators: Body mass
index and physical activitiy in relation to the incidence of hip fracture in
postmenopausal women. J Bone Miner Res 2011, 26:1330–1338.
12. Hospital Episode Statistics. [www.hesonline.nhs.uk] (2009, date last accessed).
13. Kendrick S, Clarke J: The Scottish record linkage system. Health Bull (edinb)
1993, 51:72–79.
14. World Health Organization1992International Statistical Classification of
Diseases and Related Health Problems10World Health
OrganizationGenevaWorld Health Organization: International Statistical
Classification of Diseases and Related Health Problems. 10th edition. Geneva:
World Health Organization; 1992.
15. Townsend P, Phillimore P, Beattie A: Health and deprivation: inequality and
the North. London: Croom Helm; 1988.16. Statacorp: Statistical Software: Release 10.1. TX: Stata: college Station; 2009.
17. Easton DF, Peto R, Babiker AG: Floating absolute Risk: an alternative to
relative risk in survival and case–control analysis avoiding an arbitrary
reference group. Stat Med 1991, 10:1025–1035.
18. Elian M, Dean G: The changing mortality from motor neurone disease
and multiple sclerosis in England and Wales and the Republic of Ireland.
Neuroepidemiology 1992, 11:236–243.
19. Worms PM: The epidemiology of motor neuron diseases: a review of
recent studies. J Neurol Sci 2001, 91(1–2):3–9.
20. Day TG, Scott M, Perring R, Doyle P: Motor neuron disease mortality in
Great Britain continues to rise: examination of mortality rates 1975–2004.
Amyotroph Lateral Scler 2007, 8:337–342.
21. Marin B, Couratiera P, Preuxa PM, Logroscinod G: Can mortality data be
used to estimate amyotrophic lateral sclerosis incidence?
Neuroepidemiology 2011, 36:29–38.
22. Mitchell JS, Gardham J, Mitchell C, Dixon M, Addison-Jones R, Bennett W,
O’Brien MR: Timelines in the diagnostic evaluation of people with
suspected amyotrophic lateral sclerosis (ALS)/motor neuron disease
(MND) – a 20-year review: Can we do better? Amyotroph Lateral Sclerosis
2010, 11(6):537–541.
23. Cairns BJ, Liu B, Clennell S, Cooper R, Reeves GK, Beral V, Kuh D: Lifetime
body size and reproductive factors: comparisons of data recorded
prospectively with self reports in middle age. BMC Med Res Methodol
2011, 11:7.
24. Peto R: Current misconception 3: that subgroup-specific trial mortality
results often provide a good basis for individualising patient care. Br J
Cancer 2011, 104:1057–1058.
doi:10.1186/1471-2377-12-25
Cite this article as: Doyle et al.: Incidence of and risk factors for Motor
Neurone Disease in UK women: a prospective study. BMC Neurology 2012
12:25.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
